Intellia Therapeutics Stock Jumps 4%, Adding $59 Million In Market Value

The gene-editing developer's latest quarter brought a 48% revenue decline and a $127.5 million net loss.

Share
Intellia Therapeutics Stock Jumps 4%, Adding $59 Million In Market Value

Intellia Therapeutics, which develops gene-editing treatments for severe diseases, jumped 4.3% to $10.12 in Monday trading, as of 9:59 AM ET, adding $59 million in market value. NTLA shares were on pace for their third gain of 3% or more this month.

A Rebound Within A Monthly Slide

Monday's advance left Intellia Therapeutics with a market value of about $1.4 billion, while its shares remained 45% below their 52-week high.

The stock was up 8% for the year at Friday's close, trailing the S&P 500's 11% gain. That year-to-date performance included a 19% decline over the previous month.

Intellia Therapeutics said in Friday's amended SEC filing that it had corrected the category used to describe Thursday's investor presentation. The original report otherwise stayed unchanged.

Revenue Falls As Lonvo-z Advances

Third-quarter revenue totaled $7.2 million, down 48% from a year earlier, according to Intellia Therapeutics' quarterly SEC filing. The company recorded a net loss of $127.5 million for the quarter.

Intellia Therapeutics outlined plans for seeking approval and launching lonvoguran ziclumeran, or lonvo-z, in Thursday's investor presentation. The experimental treatment targets hereditary angioedema, a disease that causes repeated swelling attacks.

The company's technology uses CRISPR to change DNA. Its lead experimental treatments are designed to be given through a single intravenous infusion, making their development central to its business.

Two Treatments And Shared Development Costs

Intellia Therapeutics' annual report for 2025 placed both lonvo-z and nexiguran ziclumeran in late-stage clinical development. Nexiguran ziclumeran targets transthyretin amyloidosis, in which protein accumulation damages tissues and organs.

The company develops treatments on its own and through partnerships, including with Regeneron. Its clinical studies operate across multiple countries, and its technology-licensing agreements involve payments, royalties and shared costs.

Regeneron shares approximately 25% of global development costs and commercial profits for the transthyretin amyloidosis program.

For lonvo-z, Intellia Therapeutics' stated plan runs from obtaining approval to launching the treatment for patients with hereditary angioedema.

Sources

More on Intellia Therapeutics

All Intellia Therapeutics (NTLA) coverage →